Currently, there are 106.00M common shares owned by the public and among those 99.09M shares have been available to trade.
The company’s stock has a 5-day price change of 51.92% and 72.79% over the past three months. ITCI shares are trading 52.29% year to date (YTD), with the 12-month market performance up to 88.21% higher. It has a 12-month low price of $62.78 and touched a high of $98.39 over the same period. ITCI has an average intraday trading volume of 622.25K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 46.41%, 47.06%, and 67.19% respectively.
Institutional ownership of Intra-Cellular Therapies Inc (NASDAQ: ITCI) shares accounts for 90.68% of the company’s 106.00M shares outstanding.
It has a market capitalization of $13.48B and a beta (3y monthly) value of 0.66. The earnings-per-share (ttm) stands at -$0.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.69% over the week and 3.26% over the month.
Earnings per share for the fiscal year are expected to increase by 57.40%, and 159.32% over the next financial year.
Looking at the support for the ITCI, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on September 06, 2024, with the firm’s price target at $68-$92. Robert W. Baird coverage for the Intra-Cellular Therapies Inc (ITCI) stock in a research note released on January 03, 2024 offered a Outperform rating with a price target of $83. TD Cowen was of a view on December 11, 2023 that the stock is Outperform, while Morgan Stanley gave the stock Overweight rating on April 20, 2023, issuing a price target of $80. Goldman on their part issued Neutral rating on August 22, 2022.
